/
ENVB
$1.38-$0.04 (-2.83%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.7M
4M shares
52-week range
$1.26 – $17.64
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
109.36%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-20698.63
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $43.0M | $39.9M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $34.0M | $31.8M | $120.9K | $681.6K | $435.2K | $408.0K | $337.5K | $200.9K |
| Gross profit | $9.0M | $8.2M | −$120.9K | −$681.6K | −$435.2K | −$408.0K | −$337.5K | −$200.9K |
| Gross margin | 20.9% | 20.4% | — | — | — | — | — | — |
| R&D | $0 | $0 | $174.1K | $4.8M | $8.0M | $7.3M | $2.8M | $2.8M |
| Operating income | −$7.1M | −$6.3M | −$5.6M | −$25.9M | −$20.0M | −$16.4M | −$9.6M | −$8.8M |
| EBITDA | −$6.9M | −$2.3M | −$6.3M | −$55.7M | −$19.5M | −$16.9M | −$9.2M | −$8.6M |
| Net income | −$16.9M | −$5.6M | −$6.9M | −$49.0M | −$18.5M | −$17.3K | −$9.6M | −$12.1M |
| Net margin | -39.3% | -14.0% | — | — | — | — | — | — |
| EPS (diluted) | -42616.68 | -2543.88 | -666.00 | -1244.28 | -156.00 | -97.08 | -228.48 | -36.24 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $10M | $-315.00 | $-315.00–$-315.00 | 1 |
| 2027 | $15M | $-111.60 | $-111.60–$-111.60 | 1 |
| 2028 | $25M | $-43.20 | $-43.20–$-43.20 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$12.39
Price
$1.38
Implied upside
+801%
Peer comparison
Enveric Biosciences, Inc. Common Stock
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
www.enveric.com- Employees
- 6
- IPO / List date
- Aug 24, 1995
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds ENVB.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ENVB as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-10-28 | 1-for-12reverse |
| 2025-01-29 | 1-for-15reverse |
| 2022-07-15 | 1-for-50reverse |
| 2019-11-25 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded ENVB yet.
